NxStage Medical, Inc. (NXTM) Reports In-Line Q3 EPS, Updates Q4 and FY11 Guidance
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Join SI Premium – FREE
NxStage Medical, Inc. (NASDAQ: NXTM) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million versus the consensus estimate of $53.87 million.
NxStage Medical, Inc. sees Q4 2011 EPS of $-0.10-$-0.08, versus the consensus of $-0.09. NxStage Medical, Inc. sees Q4 2011 revenue of $55.5-$56.5 million, versus the consensus of $56.2 million.
NxStage Medical, Inc. sees FY2011 EPS of $-0.43-$-0.36, versus the consensus of $-0.40. NxStage Medical, Inc. sees FY2011 revenue of $216-$217 million, versus prior guidance of $210-$215 million and the consensus of $214.39 million.
NxStage Medical, Inc. sees Q4 2011 EPS of $-0.10-$-0.08, versus the consensus of $-0.09. NxStage Medical, Inc. sees Q4 2011 revenue of $55.5-$56.5 million, versus the consensus of $56.2 million.
NxStage Medical, Inc. sees FY2011 EPS of $-0.43-$-0.36, versus the consensus of $-0.40. NxStage Medical, Inc. sees FY2011 revenue of $216-$217 million, versus prior guidance of $210-$215 million and the consensus of $214.39 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
